Scientists test 'Switchable' cell therapy to tame rogue immune systems
NCT ID NCT06913608
Summary
This early-stage study aimed to test the safety and effectiveness of a new two-part treatment for severe autoimmune diseases like lupus, scleroderma, and inflammatory muscle disease. The treatment involved collecting a patient's own immune cells (T cells), engineering them to target the disease, and giving them back alongside a control drug. The trial was designed to see if this combination could reduce disease activity, but it was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.